By annette
with a poster titled “Perspective Mismatch and Static Assumptions: Re-Thinking How Drug Prices Are Specified in U.S. Economic Analyses The U.S. Second Panel on Cost-Effectiveness and the ISPOR Drug Cost Task Force recommend that prices in economic evaluations reflect stakeholder “opportunity costs”. In practice, this is frequently violated: (1) price metrics often fail to reflect …
By annette
Cancer is the leading cause of death in Slovenia, placing a significant and growing burden on patients, families, and the healthcare system. While Slovenia has made notable strides — with cancer mortality declining steadily over two decades and five-year survival reaching 61% — challenges remain in prevention, data infrastructure, workforce capacity, and equitable access to …
By annette
At the 14th Adriatic Congress of Pharmacoeconomics and Outcomes Research, held in Brijuni (Croatia) on 23–25 April, Thomas Hofmarcher and Urška Kosir were contributing to key discussions on how to translate evidence into better patient access across Central and Eastern Europe. Thomas presented around the question “Are we investing enough in cancer care – and does …
By annette
Despite having one of the highest cervical cancer burdens in the EU, Romania has shown real momentum for change. Recent legislative progress on HPV vaccination, together with the adoption of a national screening methodology aligned with EU recommendations, signals a strong and growing political commitment. This new IHE-report presents a clear, evidence-based roadmap to support …
By annette
The ASPIRE Regional Summit brought together policymakers, clinicians, researchers, patient advocates, and industry partners from across Asia Pacific to accelerate translation of the ASPIRE White Paper on Lung Cancer into action and implementation at the local country level. Thomas Hofmarcher presented on IHE’s work to develop a dashboard-style framework with measurable key performance indicators (KPIs) …
By annette
IHE joined the Hyvinvointi investointina (Wellbeing as an investment) event in Helsinki on April 23 to discuss how we can turn health into a driver of both wellbeing and economic sustainability. Thomas Hofmarcher took the example of cancer and offered the following key takeaways: Innovation is essential – progress in cancer outcomes is driven by …
By annette
How does cancer care in Finland compare to national goals, Nordic peers, and European benchmarks? This dashboard-style report provides a visual and quantitative description of selected performance indicators in all areas of cancer care. The analysis draws on both national and international data sources. Finland has a substantial cancer burden due to its old population …
By annette
“Why is Finland falling behind in cancer care compared to its Nordic neighbors?” is the theme of a new investigative documentary by Finland’s public broadcaster YLE. The documentary begins by noting that Finland – along with Sweden – was a world leader in cancer survival rates just 15–20 years ago. But since then, Finland has …
By annette
At the Patient Advocacy Forum: Early Access to Oncology, on the sidelines of ESMO Latin America 2026, Andrea Manzano joined virtually to present findings from the Bridging the Gap in Women’s Cancer Care report. The presentation highlighted that women’s cancers in Latin America represent a significant and growing health challenge, with breast cancer accounting for …
By annette
Croatia has the second highest cancer incidence rate and the highest cancer mortality rate in the EU. Although five-year survival rates have increased from 44% in the early 2000s to 59% in 2019-2023, the country lags behind other EU countries. Cancer care expenditure per capita are the second lowest in the EU. In the opening …